China CDE Issues Clinical Evaluation Guidelines for Drug Clinical Trial & Marketing Authorization Applications

On April 8, 2026, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) published two technical guidelines on clinical evaluation for drug applications. One guideline addresses drug clinical trial application, while the other addresses drug marketing applications. Both documents took effect on the date of publication.

The guidelines are broadly applicable to chemical drugs and therapeutic biological products and are relevant to both domestic and overseas drug developers. For international pharmaceutical and biotech companies, the implications are particular important where global development programs, multinational clinical trials, or foreign clinical data are intended to support China registration. 

Together, the guidelines provide clearer insight into how CDE evaluates clinical rationale, scientific validity, patient protection, evidence sufficiency, labeling support, and overall benefit-risk across the product lifecycle – from clinical trial authorization through marketing approval.

What the New CDE Guidelines Signal for Drug Development and Registration in China

The two guidelines are best understood as clinical evaluation frameworks rather than additional documentation requirements. Considered together, they show how CDE expects the scientific and clinical logic of a drug application to be developed and justified from the clinical trial stage through to marketing authorization.

At the clinical trial application stage, the focus is whether the proposed clinical development strategy and trial protocol are:

1. Scientifically justified
2. Supported by adequate prior nonclinical and/or clinical evidence
3. Designed with appropriate patient protection and safety risk-control measures

At the marketing application stage, the focus shifts to whether the submitted evidence sufficiently supports: Clinical efficacy, safety, proposed indication and target population, dosage and administration, labeling, and overall benefit-risk assessment.

The practical message is clear: CDE expects a coherent and traceable clinical evidence package that links development rationale, trial design, evidence generation, and benefit-risk justification throughout the product lifecycle.

For overseas sponsors, this also means that China strategy should not begin only at the submission stage. Considerations related to China clinical practice, patient population, comparator selection, endpoint strategy, dose justification, and the applicability of global clinical data may need to be addressed earlier in global development planning.

Clinical Trial Applications: CDE Evaluates Scientific and Clinical Justification Before the Trial Starts

The clinical trial application guideline is intended to improve drug clinical development efficiency and support scientifically sound trial design. It provides technical considerations for evaluating whether a proposed clinical trial is sufficiently justified to proceed in China.

This reinforces that a clinical trial application is not merely an administrative filing step. According to the guideline, clinical evaluation should consider:

• The target indication and unmet medical need
• Prior nonclinical and clinical evidence
• The overall clinical development plan
• The proposed protocol design
• The current balance of anticipated benefit and risk.

Clinical Rationale Must Be Scientifically and Clinically Coherent

For both domestic and overseas applicants, the clinical rationale should clearly explain why the proposed drug, indication, and development strategy are scientifically appropriate. The application should connect:

• Disease background and unmet medical need
• Drug mechanism of action
• Existing nonclinical and/or clinical evidence
• Development objectives
• Proposed clinical development strategy

This becomes particularly important when a sponsor intends to rely on multinational or  foreign clinical data. While global evidence may support development, applicants should explain whether the assumptions underlying those data remain applicable to Chinese patients and China’s clinical practice environment.

Relevant considerations may include:

• Regional, ethnic, racial, or epidemiological differences
• Differences in standard of care or treatment pathways
• Inclusion of Chinese participants in global development programs
• Appropriateness of dose selection, endpoints, comparator, and trial population for China

In practice, the guidance suggests that applicability to China should be integrated into the broader development rationale rather than addressed only as a late-stage regulatory explanation.

Protocol Design and Risk Control Are Central to Trial Authorization

The guideline also reinforces that CDE will closely evaluate whether the proposed protocol is scientifically robust and whether participant protection measures are adequate.

Important clinical trial application considerations may include:

• Trial objectives and endpoint selection
• Inclusion and exclusion criteria
• Dose selection and dose-escalation strategy
• Safety monitoring arrangements
• Stopping rules and risk-control measures
• PK, PD, and PK/PD assessment plans where relevant
• The role of the proposed study within the overall development plan

For early-phase studies, particular attention is placed on:

• Starting dose justification
• Dose-escalation design
• Adverse event monitoring
• Participant protection measures
• Management of foreseeable risks

These elements are not treated as isolated technical details. Together, they form part of that overall scientific and clinical justification for whether the trial should proceed in China.

For global development programs, this means that protocols optimized primarily for global efficiency may still need to be assessed against China-specific review expectations before submission.

Marketing Authorization Applications: The Clinical Evidence Package Must Support the Proposed Use in China

The marketing authorization application guideline addresses how CDE evaluates efficacy, safety, and benefit-risk during review of a drug marketing application. The guideline is intended to support scientific, standardized, and efficient clinical evaluation, while also helping applicants understand better the key considerations underlying CDE review.

A key point for applicants is that CDE review is not limited to whether pivotal studies achieved their primary endpoints. Reviewers will assess whether the overall evidence package adequately supports: the proposed indication, target patient population, dosage and administration, labeling claims and warnings, risk management measures, and overall benefit-risk assessment.

Foreign Clinical Data Should Be Scientifically Contextualized for China

For overseas applicants, the China marketing authorization application should not be approached simply as an administrative transfer of a global dossier. Even where evidence is generated globally, the application should explain why the data  support the proposed use in China.

This may require discussion of:

• China’s current treatment landscape and standard of care
• Differences between Chinese and global clinical practice
• Ethnic or regional sensitivity considerations
• Chinese subgroup analysis where available
• Overseas regulatory or post-marketing experience.

The stronger the connection between the global evidence package and the proposed China use scenario, the easier it is for reviewers to follow the scientific and clinical logic supporting approval.

Benefit-Risk Assessment Must Be Consistent Across the Dossier

Benefit-risk evaluation is positioned as a central component of marketing authorization review. Applicants are expected to connect efficacy findings, identified and potential safety risks, clinical value, remaining uncertainties, and proposed risk management measures.

Importantly, this benefit-risk position should remain internally consistent across: Clinical summaries, clinical study reports, proposed labeling, and regulatory responses and supplemental explanations.

Even where individual studies are well designed, a weak or inconsistent benefit-risk narrative may create review challenges. CDE will assess not only what the data demonstrate, but also whether the totality of evidence sufficiently supports the proposed use of the drug in China.

Labeling and Regulatory History Should Be Evidence-Based

The guideline also emphasizes the importance of clearly explaining the product’s regulatory development and regulatory background. This may include:

• Major development milestones
• Formal interactions with regulators
• Relevant overseas scientific advice or consultations
• Overseas approval status and regulatory history where applicable

The proposed China labeling should remain fully supported by the submitted clinical evidence package. Labeling content related to indication, dosage, warnings, adverse reactions, and risk management should align with the overall clinical evidence and benefit-risk assessment.

For overseas sponsors, overseas approval may provide important supporting context, but it does not replace the need to independently justify the proposed labeling  and clinical use within the China application.

Why These Guidelines Matter for Pharmaceutical and Biotech Companies

The two guidelines make CDE’s clinical evaluation expectations more transparent. More importantly, they illustrate how CDE integrates regulatory review with clinical and scientific evaluation across the drug development lifecycle.

For pharmaceutical and biotech companies, the practical impact is likely to be felt in several areas:

• Global clinical development planning
• Multinational clinical trial design
• China Clinical trial applications
• Use of foreign clinical data for China registration
• Benefit-risk and labeling strategy
• Clinical evidence consistency across the dossier
• Alignment between global and China clinical practice considerations

These considerations are particularly relevant for innovative drugs, therapeutic biologics, and products intended for simultaneous or near-simultaneous global development and China registration

The broader message is that CDE expects a coherent and scientifically justified clinical evidence story. That story should begin with clinical need and development rationale, continue through protocol design and patient protection, and ultimately support efficacy, safety, labeling, and benefit-risk at the marketing authorization stage.

Recommended Actions for Pharmaceutical and Biotech Companies

Companies planning clinical development or registration activities in China should consider reviewing current and planned programs against the new CDE clinical evaluation considerations before development and regulatory strategies are finalized.

Recommended actions may include:

• Assess whether global development strategies adequately address China clinical evaluation expectations
• Confirm that trial protocols include clear scientific rationale and appropriate patient protection measures
• Review whether dose selection, endpoints, comparators, and monitoring strategies are adequately justified for China
• Evaluate whether Chinese patient applicability, ethnic sensitivity, and standard of care differences have been sufficiently considered
• Align efficacy, safety, benefit-risk, and labeling positions across the submission package
• Identify whether additional justification, subgroup analyses, or China-specific evidence may be needed to support review

Early assessment may help sponsors prepare more scientifically robust and better justified China submissions, while reducing downstream review questions and development delays.

Final Thoughts

The new CDE guidelines reinforce that a China drug application is expected to present more than a completed clinical data package. Sponsors are expected to demonstrate a coherent scientific and clinical rationale explaining why the drug should be studied or approved in China, how patient risks are managed, and how the evidence supports the proposed indication, dosage, labeling, and benefit-risk position.

For global development programs, one of the central question will increasingly be whether existing evidence is sufficiently applicable to China or whether additional justification or supporting evidence may be required.

Companies navigating these questions across clinical development, clinical evaluation, and registration strategy can work with Cisema to assess China submission readiness, interpret evolving CDE expectations, and prepare clinical trial and marketing authorization strategies for China.

Further Information

• Discover Cisema’s Pharmaceutical consulting services

References

• CDE Guidance on Clinical Evaluation Considerations for Drug Marketing Applications
• CDE Guidance on Improving Clinical Development Efficiency and Scientific Trial Design 

‍